PMC:7463108 / 86168-86608 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T834","span":{"begin":127,"end":132},"obj":"Body_part"},{"id":"T835","span":{"begin":151,"end":154},"obj":"Body_part"}],"attributes":[{"id":"A834","pred":"fma_id","subj":"T834","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A835","pred":"fma_id","subj":"T835","obj":"http://purl.org/sig/ont/fma/fma278683"}],"text":"Values are luminescence intensity ± SEM from 3 to 5 independent experiments at 18 h post-infection (*p \u003c 0.005 vs. un-infected cells; $p \u003c 0.05 vs. R5 HIV-1; #p \u003c 0.05 vs. R5 + morphine (M); ¶p \u003c 0.05 vs. R5 + maraviroc (MVC); §p \u003c 0.05 vs. R5 + M + MVC; ¥p \u003c 0.05 vs. R5 + M + MVC + naltrexone). (a–b) Modified and reprinted with permission from Arnatt et al. (2016). (c–e) Modified and reprinted with permission from El-Hage et al. (2013)"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T189","span":{"begin":89,"end":98},"obj":"Disease"},{"id":"T190","span":{"begin":148,"end":150},"obj":"Disease"},{"id":"T191","span":{"begin":172,"end":174},"obj":"Disease"},{"id":"T192","span":{"begin":205,"end":207},"obj":"Disease"},{"id":"T193","span":{"begin":241,"end":243},"obj":"Disease"},{"id":"T194","span":{"begin":269,"end":271},"obj":"Disease"}],"attributes":[{"id":"A189","pred":"mondo_id","subj":"T189","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A190","pred":"mondo_id","subj":"T190","obj":"http://purl.obolibrary.org/obo/MONDO_0016654"},{"id":"A191","pred":"mondo_id","subj":"T191","obj":"http://purl.obolibrary.org/obo/MONDO_0016654"},{"id":"A192","pred":"mondo_id","subj":"T192","obj":"http://purl.obolibrary.org/obo/MONDO_0016654"},{"id":"A193","pred":"mondo_id","subj":"T193","obj":"http://purl.obolibrary.org/obo/MONDO_0016654"},{"id":"A194","pred":"mondo_id","subj":"T194","obj":"http://purl.obolibrary.org/obo/MONDO_0016654"}],"text":"Values are luminescence intensity ± SEM from 3 to 5 independent experiments at 18 h post-infection (*p \u003c 0.005 vs. un-infected cells; $p \u003c 0.05 vs. R5 HIV-1; #p \u003c 0.05 vs. R5 + morphine (M); ¶p \u003c 0.05 vs. R5 + maraviroc (MVC); §p \u003c 0.05 vs. R5 + M + MVC; ¥p \u003c 0.05 vs. R5 + M + MVC + naltrexone). (a–b) Modified and reprinted with permission from Arnatt et al. (2016). (c–e) Modified and reprinted with permission from El-Hage et al. (2013)"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T894","span":{"begin":79,"end":81},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T895","span":{"begin":127,"end":132},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T896","span":{"begin":298,"end":299},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T897","span":{"begin":300,"end":301},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"}],"text":"Values are luminescence intensity ± SEM from 3 to 5 independent experiments at 18 h post-infection (*p \u003c 0.005 vs. un-infected cells; $p \u003c 0.05 vs. R5 HIV-1; #p \u003c 0.05 vs. R5 + morphine (M); ¶p \u003c 0.05 vs. R5 + maraviroc (MVC); §p \u003c 0.05 vs. R5 + M + MVC; ¥p \u003c 0.05 vs. R5 + M + MVC + naltrexone). (a–b) Modified and reprinted with permission from Arnatt et al. (2016). (c–e) Modified and reprinted with permission from El-Hage et al. (2013)"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T13049","span":{"begin":177,"end":185},"obj":"Chemical"},{"id":"T3701","span":{"begin":210,"end":219},"obj":"Chemical"},{"id":"T318","span":{"begin":221,"end":224},"obj":"Chemical"},{"id":"T15381","span":{"begin":250,"end":253},"obj":"Chemical"},{"id":"T24754","span":{"begin":278,"end":281},"obj":"Chemical"},{"id":"T5763","span":{"begin":284,"end":294},"obj":"Chemical"}],"attributes":[{"id":"A39588","pred":"chebi_id","subj":"T13049","obj":"http://purl.obolibrary.org/obo/CHEBI_17303"},{"id":"A81396","pred":"chebi_id","subj":"T13049","obj":"http://purl.obolibrary.org/obo/CHEBI_58097"},{"id":"A23042","pred":"chebi_id","subj":"T3701","obj":"http://purl.obolibrary.org/obo/CHEBI_63608"},{"id":"A28684","pred":"chebi_id","subj":"T318","obj":"http://purl.obolibrary.org/obo/CHEBI_63608"},{"id":"A49261","pred":"chebi_id","subj":"T15381","obj":"http://purl.obolibrary.org/obo/CHEBI_63608"},{"id":"A27914","pred":"chebi_id","subj":"T24754","obj":"http://purl.obolibrary.org/obo/CHEBI_63608"},{"id":"A42022","pred":"chebi_id","subj":"T5763","obj":"http://purl.obolibrary.org/obo/CHEBI_7465"}],"text":"Values are luminescence intensity ± SEM from 3 to 5 independent experiments at 18 h post-infection (*p \u003c 0.005 vs. un-infected cells; $p \u003c 0.05 vs. R5 HIV-1; #p \u003c 0.05 vs. R5 + morphine (M); ¶p \u003c 0.05 vs. R5 + maraviroc (MVC); §p \u003c 0.05 vs. R5 + M + MVC; ¥p \u003c 0.05 vs. R5 + M + MVC + naltrexone). (a–b) Modified and reprinted with permission from Arnatt et al. (2016). (c–e) Modified and reprinted with permission from El-Hage et al. (2013)"}

{"project":"LitCovid-PubTator","denotations":[{"id":"2892","span":{"begin":422,"end":426},"obj":"Gene"},{"id":"2896","span":{"begin":151,"end":156},"obj":"Species"},{"id":"2907","span":{"begin":177,"end":185},"obj":"Chemical"},{"id":"2908","span":{"begin":284,"end":294},"obj":"Chemical"},{"id":"2910","span":{"begin":89,"end":98},"obj":"Disease"},{"id":"2911","span":{"begin":118,"end":126},"obj":"Disease"}],"attributes":[{"id":"A2892","pred":"tao:has_database_id","subj":"2892","obj":"Gene:55510"},{"id":"A2896","pred":"tao:has_database_id","subj":"2896","obj":"Tax:11676"},{"id":"A2907","pred":"tao:has_database_id","subj":"2907","obj":"MESH:D009020"},{"id":"A2908","pred":"tao:has_database_id","subj":"2908","obj":"MESH:D009271"},{"id":"A2910","pred":"tao:has_database_id","subj":"2910","obj":"MESH:D007239"},{"id":"A2911","pred":"tao:has_database_id","subj":"2911","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Values are luminescence intensity ± SEM from 3 to 5 independent experiments at 18 h post-infection (*p \u003c 0.005 vs. un-infected cells; $p \u003c 0.05 vs. R5 HIV-1; #p \u003c 0.05 vs. R5 + morphine (M); ¶p \u003c 0.05 vs. R5 + maraviroc (MVC); §p \u003c 0.05 vs. R5 + M + MVC; ¥p \u003c 0.05 vs. R5 + M + MVC + naltrexone). (a–b) Modified and reprinted with permission from Arnatt et al. (2016). (c–e) Modified and reprinted with permission from El-Hage et al. (2013)"}

{"project":"LitCovid-sentences","denotations":[{"id":"T1147","span":{"begin":0,"end":440},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Values are luminescence intensity ± SEM from 3 to 5 independent experiments at 18 h post-infection (*p \u003c 0.005 vs. un-infected cells; $p \u003c 0.05 vs. R5 HIV-1; #p \u003c 0.05 vs. R5 + morphine (M); ¶p \u003c 0.05 vs. R5 + maraviroc (MVC); §p \u003c 0.05 vs. R5 + M + MVC; ¥p \u003c 0.05 vs. R5 + M + MVC + naltrexone). (a–b) Modified and reprinted with permission from Arnatt et al. (2016). (c–e) Modified and reprinted with permission from El-Hage et al. (2013)"}

{"project":"2_test","denotations":[{"id":"32876803-27720326-62958290","span":{"begin":362,"end":366},"obj":"27720326"}],"text":"Values are luminescence intensity ± SEM from 3 to 5 independent experiments at 18 h post-infection (*p \u003c 0.005 vs. un-infected cells; $p \u003c 0.05 vs. R5 HIV-1; #p \u003c 0.05 vs. R5 + morphine (M); ¶p \u003c 0.05 vs. R5 + maraviroc (MVC); §p \u003c 0.05 vs. R5 + M + MVC; ¥p \u003c 0.05 vs. R5 + M + MVC + naltrexone). (a–b) Modified and reprinted with permission from Arnatt et al. (2016). (c–e) Modified and reprinted with permission from El-Hage et al. (2013)"}